Interferon-based regimens for chronic hepatitis C (HCV) are quite common, just like interferon-free treatments, and are extensively used in Russia because interferon is widely available to most patients. In 2013 the original Russian drug cepeginterferon alpha-2b (cepegIFN alpha-2b marketed as Algeron by Biocad, Russia) was introduced into clinical practice. The aim of this study was to assess effectiveness and safety of cepegIFN alpha-2b as part of the combination therapy with ribavirin in patients with chronic HCV infection. The study was conducted over the period from 2014 to 2016 and recruited 37 patients with chronic genotype 1 HCV infection: 22 men and 15 women (mean age of 42.0 ± 5.2 years). All of them received the following combination antiviral therapy (AT): 1.5 μg/kg cepegIFN alpha-2b once a week and 15 μg/kg ribavirin daily over the period of 48 weeks. Effectiveness of AT was assessed by the rate of sustained virological response (SVR), i. e. aviremia achieved 24 weeks after the onset of treatment. In our SVR was observed in 26 patients (70.3 %). Adverse effects seen in the course of AT were typical of interferon-based drugs and ribavirin. CepegIFN alpha-2b dosage was corrected in two patients who developed neutropenia; ribavirin dosage was corrected in 3 patients who developed anemia. Based on the obtained results, we recommend including cepegIFN alpha-2b into the combination antiviral therapy in patients with chronic HCV infection.
VIEWS 4720
Moderate vaginal dysbiosis is a shift in normal vaginal microbiota composition characterized by increased levels of opportunistic microbes and an ordinary high proportion of lactobacilli that make up 20 to 80 % of the total microbial population of the vagina. Some women with vaginal dysbiosis do not show any symptoms of the infectious inflammatory condition (IIC), which raises the question of whether their dysbiosis should be corrected. We studied the association between some parameters of the microbiota and clinical symptoms of IIC in female patients with moderate vaginal dysbiosis. Participants were distributed into two groups: group 1 included patients with clinical symptoms of IIC (n = 91), group 2 was comprised of asymptomatic patients (n = 44). Mean age was 26.9 ± 6.9 years. Vaginal microbial communities were studied using real-time polymerase chain reaction assays. Levels of six Lactobacillus species were measured in the vaginal discharge: Lactobacillus crispatus, L. iners, L. jensenii, L. gasseri, L. johnsonii, and L. vaginalis. We found that L. iners dominated the microbiota of 45 (49.5 %) symptomatic patients and only 9 (20.5 %) asymptomatic individuals (p = 0.002), unlike L. gasseri that significantly prevailed in the samples of asymptomatic patients: 23 (52.3 %) women vs 21 (23.1 %) in the group of patients with clinical signs of IIC (p = 0.001).
VIEWS 5070
Criteria of normality for the vaginal microbiota of healthy women are still a subject of discussion. A decision to assign a study participant to a group of healthy individuals is quite subjective if based on the absence of complaints and physical examination only, which renders study results ambiguous. Below we compare occurrence of the normal vaginal flora and vaginal dysbiosis in women divided into 3 groups according to the examination type (patient’s subjective evaluation of her condition, physical examination, and laboratory tests). We examined 234 women of reproductive age from Yekaterinburg (mean age was 30.3 ± 6.6 years). Microbiota composition and lactobacillus diversity (L. crispatus, L. iners, L. jensenii, L. gasseri, L. johnsonii, L. vaginalis) were evaluated by real-time polymerase chain reaction using the Femoflor assay and reagent kits by DNA-Technology, Russia. One in 5 women of reproductive age who had no health complaints was found to have dysbiosis. The normal microbiota of those women was dominated mostly by L.iners, while dominant L. crispatus were observed in every third participant. Prevailing L. crispatus were also found in the normal microbiota of 46.2 % of women who were considered healthy based on the doctor’s examination and laboratory tests. Thus, clinical evaluation of the female lower reproductive tract can be compromised by doctor’s subjectivity if not supported by laboratory tests and may overlook vaginal dysbiosis in the patient.
VIEWS 5060
Many sexually transmitted diseases are caused by bacteria. While we fairly well understand the role of some microorganisms in the development of genitourinary tract infections, there is still a vast majority of those whose contribution is unclear. It is believed that sexual partners share their genitourinary microbiota, meaning that treatment regimens should be the same for both of them. This article reports results of the study of seminal and cervical microbial communities conducted in 50 married couples who did not use barrier birth control and did not take any antibiotics at least 3 months before the study. All couples presented with complaints of primary or secondary infertility, recurrent miscarriages or sought preconceptional counseling. The mean age of male and female participants was 34.8 ± 7.8 and 30.4 ± 6.2 years, respectively. Samples of the seminal fluid and vaginal secretions were studied by real-time polymerase chain reaction (real-time PCR) with Androflor and Femoflor reagent kits. The following bacteria were more frequent in the vaginal microbiota than in the seminal fluid: Lactobacillus spp. (p < 0.005), Eubacterium spp. (p = 0.002), Gardnerella vaginalis (p = 0.002), Megasphaera spp./Velionella spp./Dialister spp. (p = 0.004). Ureaplasma spp. was 3 times more frequent in women, Mycoplasma hominis was 4 times more frequent in men; however, this difference was not significant.  In 4 (8 %) couples both partners had normal microbiota; 23 (46 %) couples shared at least one microbiota resident. Also, microbial communities were totally different in 23 couples. The obtained data indicate that both sexual partners should be examined to decide on the most effective treatment for each of them. Qualitative and quantitative real-time PCR assays Androflor and Femoflor provide comprehensive data essential for adequate treatment planning.
VIEWS 5204